EULAR 2019

European Congress of Rheumatology

Letter from the Editor

Cohort study shows improvement during 25 years of RA treatment

Filgotinib in RA patients with inadequate response or naïve to methotrexate

Clinical effectiveness of fenebrutinib in RA patients with methotrexate or TNFi failure

Peficitinib likely efficacious and safe

Short methotrexate stop is safe in patients with RA

Tofacitinib is safe according to real-world data analysis

Switching upadacitinib and adalimumab is beneficial in refractory RA

Tapering of prednisone in RA patients who achieved low disease activity or remission with tocilizumab

Efficacy and safety of E6011 in RA patients with inadequate response to methotrexate

Preliminary efficacy and safety data of RG6125 in RA patients with an inadequate response to TNF inhibitors

Integrated 10-year analysis confirms safety profile abatacept

Switching among multiple infliximab biosimilars does not cause immunogenicity

Switch to sarilumab from adalimumab is efficacious and safe

Treat-to-target approach emerging in axial spondyloarthritis

NSAIDs consumption is linked to patient-assessed disease activity and decreases with use of TNF inhibitors

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Efficacy and safety of bimekizumab in patients with active PsA

Filgotinib is efficacious and safe in PsA

Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

Etanercept and methotrexate as first-line treatment in PsA

Unacceptable pain is common in patients with psoriatic arthritis

What Is New in Osteoarthritis

How to Treat Osteoporosis

Interstitial lung disease in rheumatic diseases and systemic sclerosis

Emapalumab in patients with macrophage activation syndrome

Support for tocilizumab use in giant cell arteritis

Top image: @ iStockPhoto: Suze777

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.